Vaccitech plc (VACC)
| Previous close | 4.4500 |
| Open | 4.3452 |
| Bid | 3.1000 x 900 |
| Ask | 6.9800 x 800 |
| Day's range | 4.3200 - 4.7200 |
| 52-week range | 2.9700 - 16.5000 |
| Volume | |
| Avg. volume | 14,508 |
| Market cap | 171.533M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient transaminitis. Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose. Declines were most prominent in patients with lower baseline HBsAg. All patients
- GlobeNewswire
Vaccitech to Present at the Jefferies Healthcare Conference
OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City. A live webcast of the pr
- GlobeNewswire
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapyWARMINSTER, Pa. and OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and develop
